These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

963 related articles for article (PubMed ID: 24328678)

  • 21. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.
    Zhu YX; Braggio E; Shi CX; Kortuem KM; Bruins LA; Schmidt JE; Chang XB; Langlais P; Luo M; Jedlowski P; LaPlant B; Laumann K; Fonseca R; Bergsagel PL; Mikhael J; Lacy M; Champion MD; Stewart AK
    Blood; 2014 Jul; 124(4):536-45. PubMed ID: 24914135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs.
    Fuchs O
    Cardiovasc Hematol Disord Drug Targets; 2019; 19(1):51-78. PubMed ID: 29788898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs.
    Gemechu Y; Millrine D; Hashimoto S; Prakash J; Sanchenkova K; Metwally H; Gyanu P; Kang S; Kishimoto T
    Proc Natl Acad Sci U S A; 2018 Nov; 115(46):11802-11807. PubMed ID: 30373817
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Fink EC; McConkey M; Adams DN; Haldar SD; Kennedy JA; Guirguis AA; Udeshi ND; Mani DR; Chen M; Liddicoat B; Svinkina T; Nguyen AT; Carr SA; Ebert BL
    Blood; 2018 Oct; 132(14):1535-1544. PubMed ID: 30064974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.
    Lu G; Middleton RE; Sun H; Naniong M; Ott CJ; Mitsiades CS; Wong KK; Bradner JE; Kaelin WG
    Science; 2014 Jan; 343(6168):305-9. PubMed ID: 24292623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL.
    Hagner PR; Chiu H; Chopra VS; Colombo M; Patel N; Estevez MO; Waldman MF; Loos R; Towfic F; Gandhi AK
    Clin Cancer Res; 2022 Aug; 28(15):3367-3377. PubMed ID: 35583604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Development of novel cereblon modulators and their target molecules].
    Ito T
    Rinsho Ketsueki; 2022; 63(6):573-579. PubMed ID: 35831190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting cereblon in hematologic malignancies.
    Fuchs O
    Blood Rev; 2023 Jan; 57():100994. PubMed ID: 35933246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lenalidomide induces degradation of IKZF1 and IKZF3.
    Krönke J; Hurst SN; Ebert BL
    Oncoimmunology; 2014; 3(7):e941742. PubMed ID: 25610725
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PLZF and its fusion proteins are pomalidomide-dependent CRBN neosubstrates.
    Shimizu N; Asatsuma-Okumura T; Yamamoto J; Yamaguchi Y; Handa H; Ito T
    Commun Biol; 2021 Nov; 4(1):1277. PubMed ID: 34764413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase.
    Matyskiela ME; Lu G; Ito T; Pagarigan B; Lu CC; Miller K; Fang W; Wang NY; Nguyen D; Houston J; Carmel G; Tran T; Riley M; Nosaka L; Lander GC; Gaidarova S; Xu S; Ruchelman AL; Handa H; Carmichael J; Daniel TO; Cathers BE; Lopez-Girona A; Chamberlain PP
    Nature; 2016 Jul; 535(7611):252-7. PubMed ID: 27338790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. USP15 antagonizes CRL4
    Nguyen TV
    Proc Natl Acad Sci U S A; 2021 Oct; 118(40):. PubMed ID: 34583995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thalidomide Inhibits Human iPSC Mesendoderm Differentiation by Modulating CRBN-dependent Degradation of SALL4.
    Belair DG; Lu G; Waller LE; Gustin JA; Collins ND; Kolaja KL
    Sci Rep; 2020 Feb; 10(1):2864. PubMed ID: 32071327
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon.
    Nguyen TV; Lee JE; Sweredoski MJ; Yang SJ; Jeon SJ; Harrison JS; Yim JH; Lee SG; Handa H; Kuhlman B; Jeong JS; Reitsma JM; Park CS; Hess S; Deshaies RJ
    Mol Cell; 2016 Mar; 61(6):809-20. PubMed ID: 26990986
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide.
    Tateno S; Iida M; Fujii S; Suwa T; Katayama M; Tokuyama H; Yamamoto J; Ito T; Sakamoto S; Handa H; Yamaguchi Y
    Sci Rep; 2020 Mar; 10(1):4012. PubMed ID: 32132601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The E3 ubiquitin ligase component, Cereblon, is an evolutionarily conserved regulator of Wnt signaling.
    Shen C; Nayak A; Neitzel LR; Adams AA; Silver-Isenstadt M; Sawyer LM; Benchabane H; Wang H; Bunnag N; Li B; Wynn DT; Yang F; Garcia-Contreras M; Williams CH; Dakshanamurthy S; Hong CC; Ayad NG; Capobianco AJ; Ahmed Y; Lee E; Robbins DJ
    Nat Commun; 2021 Sep; 12(1):5263. PubMed ID: 34489457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus.
    Schafer PH; Ye Y; Wu L; Kosek J; Ringheim G; Yang Z; Liu L; Thomas M; Palmisano M; Chopra R
    Ann Rheum Dis; 2018 Oct; 77(10):1516-1523. PubMed ID: 29945920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Discovery of the target for immunomodulatory drugs (IMiDs)].
    Ito T; Ando H; Handa H
    Rinsho Ketsueki; 2016 May; 57(5):556-62. PubMed ID: 27263779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.
    Zhu YX; Braggio E; Shi CX; Bruins LA; Schmidt JE; Van Wier S; Chang XB; Bjorklund CC; Fonseca R; Bergsagel PL; Orlowski RZ; Stewart AK
    Blood; 2011 Nov; 118(18):4771-9. PubMed ID: 21860026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The molecular mechanism of thalidomide analogs in hematologic malignancies.
    Lindner S; Krönke J
    J Mol Med (Berl); 2016 Dec; 94(12):1327-1334. PubMed ID: 27492707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.